Research in regenerative medicine is based on rapid advances in the field of stem cells, tissue engineering and patient-derived models. Ethical limitations encourage the use of pluripotent stem cells derived from adult patients rather than the use of fetal cells. C is the case of iPS-induced pluripotent cells whose differentiation makes it possible to obtain many cell types that can be used directly in the clinic. We propose the creation of a bioproduction site on the Institute of Research in Regenerative Medicine Biotherapies (IRMB) located on the site of the CHU Montpellier, dedicated to cell therapy, with a specialisation on human induced pluripotent stem cells (iPS) of clinical grade. The production of iPS will allow the development of new biomedicines that can promote the regeneration of deficient cells, tissues and organs in humans.